Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: An isobolographic analysis

European Journal of Pharmacology

Volumn 605, Issue 1-3, 2009, Pages 87-94

  Dudra Jastrzebska, Monika ^a,b   Andres Mach, Marta M ^b   Sielski, Marcin ^a   Ratnaraj, Neville ^c   Patsalos, Philip N ^c   Czuczwar, Stanislaw J ^a,b   Luszczki, Jarogniew J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiepileptic drug; Gabapentin; Isobolographic analysis; Levetiracetam; Pentylenetetrazole; Pharmacodynamic interaction; Pharmacokinetic interaction; Tiagabine; Vigabatrin

Indexed keywords

ETIRACETAM; GABAPENTIN; PENTETRAZOLE; TIAGABINE; VIGABATRIN;

ANIMAL EXPERIMENT; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG POTENTIATION; GRIP STRENGTH; LONG TERM MEMORY; MALE; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NONHUMAN; PASSIVE AVOIDANCE; PHARMACODYNAMICS; PRIORITY JOURNAL;

AMINES; ANIMALS; ANTICONVULSANTS; BRAIN; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG SYNERGISM; GAMMA-AMINOBUTYRIC ACID; MALE; MICE; NIPECOTIC ACIDS; PENTYLENETETRAZOLE; PIRACETAM; SEIZURES; TISSUE DISTRIBUTION; VIGABATRIN;

EID: 60349092371     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.12.046     Document Type: Article

References (54)

1. Barton M.E., Klein B.D., Wolf H.H., and White H.S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy. Res. 47 (2001) 217-227
2. Boissier J.R., Tardy J., and Diverres J.C. Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med. Exp. (Basel). 3 (1960) 81-84
3. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-442
4. Czuczwar S.J., and Patsalos P.N. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS. Drugs. 15 (2001) 339-350
5. Donato Di Paola E., Gareri P., Davoli A., Gratteri S., Scicchitano F., Naccari C., and De Sarro G. Influence of levetiracetam on the anticonvulsant efficacy of conventional antiepileptic drugs against audiogenic seizures in DBA/2 mice. Epilepsy. Res. 75 (2007) 112-121
6. Frucht S.J., Louis E.D., Chuang C., and Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 57 (2001) 1112-1114
7. 2δ subunit of calcium channel. J. Biol. Chem 271 (1996) 5768-5776
8. Glauser T.A., Pellock J.M., Bebin E.M., Fountain N.B., Ritter F.J., Jensen C.M., and Shields W.D. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43 (2002) 518-524
9. Goldlust A., Su T.Z., Welty D.F., Taylor C.P., and Oxender D.L. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy. Res. 22 (1995) 1-11
10. Gower A.J., Hirsch E., Boehrer A., Noyer M., and Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy. Res. 22 (1995) 207-213
11. Gower A.J., Noyer M., Verloes R., Gobert J., and Wulfert E. Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol 222 (1992) 193-203 Erratum published in: 1993. Eur. J. Pharmacol 230, 389
12. Grant R., and Shorvon S.D. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy. Res. 42 (2000) 89-95
13. Jensen A.A., Mosbacher J., Elg S., Lingenhoehl K., Lohmann T., Johansen T.N., Abrahamsen B., Mattsson J.P., Lehmann A., Bettler B., and Brauner-Osborne H. The anticonvulsant gabapentin (neurontin) does not act through gamma-aminobutyric acid-B receptors. Mol. Pharmacol 61 (2002) 1377-1384
14. Kaminski, R.M., Matagne, A., Patsalos, P.N., Klitgaard, H., in press. Benefits of combination therapy in epilepsy: a review of preclinical evidence with levetiracetam. Epilepsia. doi:10.1111/j.1528-1167.2008.01713.x.
15. Kaminski R.M., Matagne A., Leclercq K., Gillard M., Michel P., Kenda B., Talaga P., and Klitgaard H. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54 (2008) 715-720
16. Kasteleijn-Nolst Trenite D.G., Marescaux C., Stodieck S., Edelbroek P.M., and Oosting J. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy. Res. 25 (1996) 225-230
17. Khurana D.S., Kothare S.V., Valencia I., Melvin J.J., and Legido A. Levetiracetam monotherapy in children with epilepsy. Pediatr. Neurol 36 (2007) 227-230
18. Klitgaard H., Matagne A., Gobert J., and Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol 353 (1998) 191-206
19. Lee C.H., Lee C.Y., Tsai T.S., and Liou H.H. PKA-mediated phosphorylation is a novel mechanism for levetiracetam, an antiepileptic drug, activating ROMK1 channels. Biochem. Pharmacol 76 (2008) 225-235
20. Lee C.H., Tsai T.S., and Liou H.H. Gabapentin activates ROMK1 channels by a protein kinase A (PKA)-dependent mechanism. Br. J. Pharmacol 154 (2008) 216-225
21. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther 96 (1949) 99-113
22. Löscher W., and Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur. J. Pharmacol 232 (1993) 147-158
23. Löscher W., Hönack D., and Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther 284 (1998) 474-479
24. Löscher W., Hönack D., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy. Res. 8 (1991) 171-189
25. Lukyanetz E.A., Shkryl V.M., and Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43 (2002) 9-18
26. Luszczki J.J., and Czuczwar S.J. How significant is the difference between drug doses influencing the threshold for electroconvulsions?. Pharmacol. Rep 57 (2005) 782-786
27. Luszczki J.J., and Czuczwar S.J. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 529-538
28. Luszczki J.J., Andres M.M., Czuczwar P., Cioczek-Czuczwar A., Wojcik-Cwikla J., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice. Eur. Neuropsychopharmacol 15 (2005) 609-616
29. Luszczki J.J., Andres M.M., Czuczwar P., Cioczek-Czuczwar A., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia 47 (2006) 10-20
30. Luszczki J.J., Andres-Mach M.M., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. Epilepsia 48 (2007) 806-815
31. Luszczki J.J., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. Eur. J. Pharmacol 595 (2008) 13-21
32. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA 101 (2004) 9861-9866
33. Madeja M., Margineanu D.G., Gorji A., Siep E., Boerrigter P., Klitgaard H., and Speckmann E.J. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?. Neuropharmacology 45 (2003) 661-671
34. Margineanu, D.G., Matagne, A., Kaminski, R.M., Klitgaard, H., in press. Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats. Brain Res. Bull (In press). doi:10.1016/j.brainresbull.2008.07.006.
35. Marrosu F., Bortolato M., Frau R., Orru M., Puligheddu M., Fa M., Muroni A., Tuveri A., and Mereu G. Levetiracetam attenuates spontaneous spike-and-wave discharges in DBA/2J mice. Epilepsy. Res. 75 (2007) 224-227
36. Mazarati A.M., Baldwin R., Klitgaard H., Matagne A., and Wasterlain C.G. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy. Res. 58 (2004) 167-174
37. Meyer O.A., Tilson H.A., Byrd W.C., and Riley M.T. A method for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav. Toxicol 1 (1979) 233-236
38. Nagarkatti N., Deshpande L.S., and DeLorenzo R.J. Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. Neurosci. Lett 436 (2008) 289-293
39. Niespodziany I., Klitgaard H., and Margineanu D.G. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci. Lett 306 (2001) 5-8
40. Palma E., Roseti C., Maiolino F., Fucile S., Martinello K., Mazzuferi M., Aronica E., Manfredi M., Esposito V., Cantore G., Miledi R., Simonato M., and Eusebi F. GABA(A)-current rundown of temporal lobe epilepsy is associated with repetitive activation of GABA(A) "phasic" receptors. Proc. Natl. Acad. Sci. USA 104 (2007) 20944-20948
41. Parker D.A.S., Ong J., Marino V., and Kerr D.I.B. Gabapentin activates presynaptic GABAB heteroreceptors in rat cortical slices. Eur. J. Pharmacol 495 (2004) 137-143
42. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet 43 (2004) 707-724
43. Porreca F., Jiang Q., and Tallarida R.J. Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur. J. Pharmacol 179 (1990) 463-468
44. Ratnaraj N., Doheny H.C., and Patsalos P.N. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography. Ther. Drug. Monit. 18 (1996) 154-157
45. Ratnaraj N., and Patsalos P.N. A high-performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin in serum. Ther. Drug. Monit. 20 (1998) 430-434
46. Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., Leprince P., Moonen G., Selak I., Matagne A., and Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br. J. Pharmacol 136 (2002) 659-672
47. Sills G.J., Butler E., Thompson G.G., and Brodie M.J. Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. Seizure 13 (2004) 287-295
48. Sisodiya S.M., Sander J.W., and Patsalos P.N. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy. Res. 48 (2002) 217-219
49. Specchio L.M., Gambardella A., Giallonardo A.T., Michelucci R., Specchio N., Boero G., and La Neve A. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy. Res. 71 (2006) 32-39
50. Tan M.J., and Appleton R.E. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure 13 (2004) 142-145
51. Taylor C.P., Gee N.S., Su T.Z., Kocsis J.D., Welty D.F., Brown J.P., Dooley D.J., Boden P., and Singh L. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy. Res. 29 (1998) 233-249
52. Venault P., Chapouthier G., de Carvalho L.P., Simiand J., Morre M., Dodd R.H., and Rossier J. Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature 321 (1986) 864-866
53. Vinogradova L.V., and van Rijn C.M. Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. Epilepsia 49 (2008) 1160-1168
54. Wang X., Ratnaraj N., and Patsalos P.N. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus). Seizure 13 (2004) 574-581